Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO)

Clinical Trial ID NCT00263042

PubWeight™ 15.56^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00263042

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.	Lancet	2010	4.72
2	A covering method for detecting genetic associations between rare variants and common phenotypes.	PLoS Comput Biol	2010	1.98
3	Biomarkers of endocannabinoid system activation in severe obesity.	PLoS One	2010	1.30
4	Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.	Physiol Behav	2007	1.13
5	Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level.	Genome Biol	2010	1.12
6	Early vascular aging (EVA): consequences and prevention.	Vasc Health Risk Manag	2008	0.80
7	The endocannabinoid system: potential for reducing cardiometabolic risk.	Obesity (Silver Spring)	2009	0.79
8	Orlistat in the prevention of diabetes in the obese patient.	Vasc Health Risk Manag	2008	0.78
9	Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.	BMC Gastroenterol	2009	0.77
10	A stepwise likelihood ratio test procedure for rare variant selection in case-control studies.	J Hum Genet	2014	0.76
11	An EM algorithm based on an internal list for estimating haplotype distributions of rare variants from pooled genotype data.	BMC Genet	2013	0.75
12	No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.	Int J Obes (Lond)	2010	0.75